drugset / Trial / NCT03960060
A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors
Phase 1
Terminated
9 enrolled
Shanghai PerHum Therapeutics Co., Ltd.
Shanghai Zhongshan Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This clinical study is to investigate the safety and tolerability of CAR modified autologous T cells (CCT301-59) in subjects with recurrent or refractory solid tumors.
Timeline
- Start
- 2019-05-16
- Primary completion
- 2022-06-30
- Completion
- 2023-06-30
Outcome
Outcome not reported
Stopped (Business): “Adjustment of study strategy”